Human immunodeficiency virus-1 (HIV-1) is a major public health threat that continues to infect millions of people worldwide each year. A prophylactic vaccine remains the most cost-effective way of globally reducing and eliminating the spread of the virus. The HIV envelope spike, which is the target of many vaccine design efforts, is densely mantled with carbohydrate and several potent broadly neutralizing antibodies to HIV-1 recognize carbohydrate on the envelope spike as a major part of their epitope. However, immunizing with recombinant forms of the envelope glycoprotein does not typically elicit anti-carbohydrate antibodies. Thus, studies of alternative antigens that may serve as a starting point for carbohydrate-based immunogens are of interest. Here, we present the crystal structure of one such anti-carbohydrate HIV neutralizing antibody (2G12) in complex with the carbohydrate backbone of the lipooligosaccharide from Rhizobium radiobacter strain Rv3, which exhibits a chemical structure that naturally mimics the core high-mannose carbohydrate epitope of 2G12 on HIV-1 gp120. The structure described here provides molecular evidence of the structural homology between the Rv3 oligosaccharide and highly abundant carbohydrates on the surface of HIV-1 and raises the potential for the design of novel glycoconjugates that may find utility in efforts to develop immunogens for eliciting carbohydrate-specific neutralizing antibodies to HIV.
Introduction
Human immunodeficiency virus-1 (HIV-1) continues to be a serious public health threat with 34 million people currently infected; less than a quarter of those have access to anti-retroviral therapies (UNAIDS 2012) . Although these anti-retroviral drugs are highly effective at controlling the virus, they are not capable of complete eradication, leaving dormant viral reservoirs that can become active when drugs are discontinued (Donahue and Wainberg 2013) . Thus, despite significant advances in therapeutic approaches and attempts to purge viral reservoirs in infected individuals, there remains a critical need for an effective HIV-1 vaccine to protect against infection.
2G12 is one of the original four broadly neutralizing antibodies (bnAbs) to HIV-1 and is still the only Ab that exclusively recognizes carbohydrate on the surface of HIV-1 (Kunert et al. 1998; Sanders et al. 2002; Stiegler et al. 2002; Calarese et al. 2003; Scanlan et al. 2003; Calarese et al. 2005; Murin et al. 2014) . 2G12 has reasonable breadth due to its recognition of a conserved epitope on gp120 that consists of oligomannose-type glycans at positions 295, 332, 339 and 392. Neighboring glycans at 386 and 448 may influence the recognition process but do not appear to directly bind to 2G12 (Murin et al. 2014) . These glycans are densely clustered on the gp120 surface and are derived from the host cell during protein synthesis. For many years, 2G12 was the only anti-HIV-1 antibody known to interact with carbohydrate; indeed, it was long thought that the dense patch of glycans on gp120 and the underlying protein surface were essentially inert to immune recognition (Wyatt et al. 1998) . However, recent exciting developments, spurred largely by advances in technologies that enable high-throughput screening of memory B-cell cultures, have revealed that many extremely potent and broadly neutralizing anti-HIV-1 antibodies can be isolated from infected individuals that recognize glycans as a major component of their epitope along with surrounding protein segments (for review, see Kong et al. 2014) . These antibodies include the PGT121 family that recognizes one or more oligomannose-and/or complex-type glycans at the base of the V3 variable region Julien, Sok, et al. 2013; Garces et al. 2014) , the PGT128 family that recognizes oligomannose-type glycans at positions 301 and 332 on gp120 , the PGT135 family that recognizes oligomannose-type glycans at positions 332, 392 and 295 and 386 depending on the isolate (Kong et al. 2013 ), PG9, PG16, PGT145 and related antibodies that recognize glyco-epitopes around positions 160 and either 156 or 173 in the gp120 V1/V2 region (Pancera et al. 2010; McLellan et al. 2011; Pancera et al. 2013; Pejchal et al. 2010) , the PGT151 family and antibody 35O22 that recognize a quaternary epitope at the gp120/gp41 interface, likely involving glycans at gp41 residues 611 and 637 (PGT151) (Blattner et al. 2014 ) and glycans at gp120 residues 88, 230 and 241 and gp41 residue 625 (35O22) , and antibody 8ANC195 that binds at the interface between gp41 and the gp120 CD4-binding site, contacting gp120 glycans at positions 234 and 276 (Scharf et al. 2014) . Thus far, crystal and electron microscopy (EM) structures of these glycandependent antibodies in complex with their HIV-derived antigens reveal at least two main areas of glycan-dependent recognition on gp120, centered on and around dense patches of glycans located at positions 332 and 160, as well as the two distinct gp120/gp41 interface epitopes recognized by the PGT151 family of antibodies and antibodies 35O22 and 8ANC195. Indeed, the recent crystal and EM structures of an HIV-1 gp140 trimer Lyumkis et al. 2013; Pancera et al. 2014) suggest that the majority of the trimer surface is covered by glycosylation, so that many if not most neutralizing epitopes are likely to involve carbohydrate components.
2G12 is unique in that it is domain swapped via its variable heavy (V H ) chain domains, resulting in a linear IgG with the two Fab regions tethered side by side . The antigen-binding sites on the two closely spaced Fab regions are ∼33 Å apart, and two nonconventional sites centered at the interface of the intertwined V H domains can also potentially interact with carbohydrate, thus yielding an inherently high-avidity-binding site for clustered glycans such as found on the gp120 high-mannose patch around glycan 332. While 2G12 uses this unusual dimer-of-Fabs assembly to interact with multiple glycan chains, the more recently discovered anti-glycan antibodies such as PGT128, PGT135, PG9, PG16, PGT151, 35O22 and 8ANC195 are all 'normal' insofar that they are non-domain-swapped IgG's; these antibodies achieve high avidity by interacting with multiple glycans within their combining site and using long complementarity determining region (CDR) loops, especially CDR H3, to penetrate the glycan shield and reach the protein surface below, thereby contacting complex epitopes made up of both glycan and protein .
Understanding the structure and location of a broadly neutralizing epitope and translating that knowledge into an effective immunogen against that region have proven difficult; however, recent results with respiratory syncytial virus Correia et al. 2014) provide optimism that structure-based immunogen design can be successful. Carbohydrates, in the form of glycoconjugates, have of course proven effective as vaccines for various bacterial pathogens, including Haemophilus influenza type b, Neisseria meningitidis serogroups A, C, Y and W-135 and Streptococcus pneumoniae (Astronomo and Burton 2010; Taylor et al. 2012) , so that investigating carbohydrate-based conjugates for prevention of HIV-1 infection is a highly attractive area for investigation.
It was recently discovered that Rhizobium radiobacter strain Rv3, a Gram-negative bacterium previously classified as Agrobacterium tumefaciens (Young et al. 2001; Farrand et al. 2003) , expresses a lipopolysaccharide on its surface with a distal segment that is chemically analogous to the D1 arm of oligomannose, which constitutes the core epitope of 2G12 (Clark et al. 2012) (Figure 1 ). Rhizobia are commonly regarded as associated with plants; some species, such as R. radiobacter, are phytopathogens that can cause crown gall disease in certain plants (reviewed in Escobar and Dandekar 2003) . R. radiobacter is increasingly recognized also as an opportunistic pathogen in human nosocomial infections associated with the use of intravenous catheters (Edmond et al. 1993; Amaya and Edwards 2003; Paphitou and Rolston 2003; Chen et al. 2008) . The lipopolysaccharide of R. radiobacter Rv3 is naturally devoid of an O-antigenic portion commonly found in the lipopolysaccharides of many other Gram-negative bacteria, and is thus termed a lipooligosaccharide (LOS); thus, the Rv3 LOS consists solely of a lipid A moiety and a core oligosaccharide (OS) region (Figure 1 ), which in turn contains inner and outer core segments . The D1-arm-like portion of the Rv3 LOS differs from the D1 arm of oligomannose where the anomeric configuration of the first branching mannose (Man2 in Figure 1 ) is α in Rv3 instead of β as found in oligomannose. The connection of this Man2 unit also differs and is to the lipopolysaccharide-specific Kdo (3-deoxy-octulosonic acid) residue in Rv3 instead of the chitobiose core in oligomannose (De Castro et al. 2008) .
Immunization of mice with heat-killed Rv3 bacteria has been shown previously to result in serum antibodies with capacity to bind monomeric HIV-1 gp120 with modest affinity (Clark et al. 2012) ; however, those sera failed to neutralize HIV-1 strains. In order to better understand the antigenic similarity between the OS backbone of the Rv3 LOS and mammalian oligomannoses and the role, if any, played by chemical differences between the Rv3 OS and oligomannose, we determined the crystal structure of Fab 2G12 in complex with the Rv3 OS to an effective resolution of 2.0 (Weiss 2001; Urzhumtseva et al. 2013) . To the best of our knowledge, these data provide the most conclusive evidence so far for the unique resemblance between a bacterial OS and mammalian oligomannose. 
Results

Oligosaccharide NMR structure
After chromatographic purification, the Rv3 core OS was isolated from the LOS in 16% yield. Its proton NMR spectra (Supplementary data, Figure S1 ) displayed five main anomeric signals in the low field region (δ 5.4-4.9), a crowded carbinolic region (δ 4.3-3.5) and two couples of methylene protons (δ 2.4-1.7) related to the α and β anomeric forms of the Kdo1 residue at the reducing end. Attribution of all protons and carbon chemical shifts (Supplementary data, Table SI) was afforded by integrating information from the homo-and heteronuclear 2D NMR spectra; their values did not diverge from those of the mannose residues reported for the full-length OS isolated after alkaline deacetylation (Clark et al. 2012 ). The only main difference was attributed to Man2, as it was affected by the anomeric status of the nearby Kdo1, which could freely interconvert among its α or β anomers. Indeed, H-1 of Man2 was found at δ 5.02 when linked at O-4 of the α isomer of Kdo1 or at δ 4.96 for the β anomer (labeled as Man2* in Supplementary data, Figure S1 ).
Analysis of the HSQC-TOCSY spectrum (Supplementary data, Figure S1B ) immediately allowed identification of the different mannose units in the OS. The two-terminal mannose, Man5 and Man6, could be assigned as their carbon chemical shifts were <75 ppm and not shifted by linkage to any further sugar units. On the contrary, C-6 of Man2 was shifted at low field (δ 66.6) because of its linkage to Man6, while, Man3 and Man4 each displayed one low field carbon signal (δ 80.0 and 79.8, respectively) that were identified as C-2 in both cases with the aid of the other NMR spectra. Analysis of HMBC spectrum (Supplementary data, Figure S1C ) confirmed the sequence of the hexasaccharide that is expected after mild acid hydrolysis of the LPS (Figure 1 , highlighted structure).
Overall crystal structure
The 2G12 Fab is dimeric, as seen previously , with the expected swap of its V H domains. Two Rv3 glycans bind to 2G12, one in each classic antibody combining site, contacting residues from CDRs H3, H1 and L3 (Figure 2 ). All six sugars of the OS have strong electron density ( Figure 3A) , with the B-values increasing as Rv3 exits the binding site. The overall carbohydrate geometry is good, with linkage torsion angles falling within normal distributions as evaluated with pdb-care (Lutteke and von der Lieth 2004; Lutteke et al. 2006 ; Supplementary data, Figure S2 ). The mannose that is bound most deeply in the binding site is Man5, which makes 10 hydrogen bonds to the Fab (Table I) . Other sugars making contact to the Fab are Man4 (6 hydrogen bonds), Man3 (2 hydrogen bonds) and Man2 (2 hydrogen bonds). The Kdo1 residue does not contact the Fab, while Man6 makes just one hydrogen bond. There are also 67 van der Waals interactions between the glycan and Fab. The two combining sites in the dimer of Fabs are very similar. When the variable domains of each Fab monomer are superimposed (Cα atoms of K1-107 and M1-113 superimposed onto L1-107 and H1-113) the root mean squared deviation (RMSD) for the superimposed Cα atoms is 0.30 Å, and the RMSD for all carbohydrate atoms is 0.81 Å. Hydrogen bonds in the two combining sites are also very well conserved (Table I) .
Comparison with 2G12 in complex with GlcNAc 2 Man 9
The crystal structure of 2G12 in complex with the Rv3 sugar is very similar to that of 2G12 in complex with GlcNAc 2 Man 9 (PDB code 1OP5; Calarese et al. 2003, resolution 3.0 Å) . When the variable regions are superimposed by Cα atoms (using residues L2-L107, H1-H113, K2-K107 and M1-M113 for the superposition), the overall RMSD is 0.73 Å, with RMSD's for CDRs L1, L2, L3, H1, H2, and H3 of 0.63 Å, 1.03 Å, 0.33 Å, 0.57 Å, 0.63 Å and 0.90 Å, respectively. The Rv3 residues Man2-Man5 superimpose well with the equivalent Bma3 (β-D-mannose 3) and Man4-Man6 of GlcNAc 2 Man 9 in 1OP5 (sugar in chain A), with RMSD for all atoms of 1.02 Å ( Figure 3B ). In the original crystal structure for 2G12 in complex with GlcNAc 2 Man 9 (PDB code 1OP5), crystal packing contacts allow the D2/D3 arms of the sugar to occupy two symmetry-related clefts located between the two paired heavy chains, suggesting that 2G12 may have up to four sites for sugar interaction. The 2G12-Rv3 structure does not have electron density in these extra pockets at the V H -V H ′ interface, which is not surprising as the Rv3 OS has no D2/D3 arm-like branches.
When comparing 2G12-Rv3 with previously determined structures for 2G12 in complex with carbohydrate ranging in complexity from Man 2 to GlcNAc 2 Man 9 , both Fab and sugar structures are highly similar, with the only differences occurring in the bacterial sugars that differ from those in GlcNAc 2 Man 9 . However, the different anomeric configuration at Man2 and the presence of the Kdo residue are not important for the binding interaction of Rv3 OS in the 2G12-binding site, making the Rv3 OS an excellent mimic of the naturally occurring GlcNAc 2 Man 9 sugar.
Discussion
The recent crystal and cryo-electron microscopy structures of a cleaved, stabilized gp140 trimer in complex with Fabs Lyumkis et al. 2013; Pancera et al. 2014) have clearly shown that the HIV-1 gp140 trimer is almost completely coated with carbohydrate. This dense arrangement of high mannose as well as some complex sugars presents an attractive target for vaccine design because it is not typical of mammalian glycosylation (Scanlan et al. 2007 ). Thus, studies of both natural and synthetic carbohydrates are of interest to vaccine design studies. In a previous study (Clark et al. 2012) , it was shown that the Rv3 LOS backbone is antigenically analogous to the D1 arm in mammalian oligomannose; soluble Rv3 LOS inhibited the binding of 2G12 to gp120 at least as good as synthetic oligomannosides or Man 9 GlcNAc 2 and the level of inhibition observed with Rv3 bacteria matched that of gp120 based on the yield of LOS extracted from bacteria. The Rv3 sugar not only has high structural homology to the D1 arm of Man 9 GlcNAc 2 , as shown in this study, but may be attractive for vaccine design because it also contains bacterial-derived sugars such as Kdo that may trigger qualitatively different antibody responses. Whether incorporation of non-mammalian carbohydrate moieties can help to trigger or boost antibody responses to oligomannose sugars on HIV needs to be explored further. A previous attempt to use synthetic non-self glycans comprised of the D1 oligomannosides with fructose termini as immunogens failed to evoke antibodies capable of recognizing gp120, even though these antibodies showed excellent binding to the D1 arm when presented in a range of other glycoconjugate formats ).
Molecular mimicry of mammalian host structures by foreign polysaccharides is of course not new (Caplan et al. 1977) ; for example, antibodies to the LOS of certain Campylobacter jejuni strains can cross-react with gangliosides expressed on mammalian cells due to chemico-structural homology (Ang et al. 2002) and the potential for autoimmunity due to mimicry between Helicobacter pylori lipopolysaccharides and host Lewis blood group antigens has been noted (Appelmelk et al. 1996) . While unnaturally glycosylated yeast have been investigated for their ability to elicit anti-oligomannose neutralizing antibodies (Luallen et al. 2008; Agrawal-Gamse et al. 2011 ), we are not aware of any report in which bacterial-based antigenic mimicry has been applied to eliciting neutralizing antibodies to HIV (or any other virus). Therefore, the Rv3 structure presented here provides impetus for further exploration. Attempts to elicit oligomannose-specific bnAbs to HIV using synthetic oligomannosides have so far not been successful Geng et al. 2004; Li and Wang 2004; Mandal et al. 2004; Wang et al. 2004; Ni et al. 2006; Astronomo et al. 2008; Joyce et al. 2008; Astronomo and Burton 2010; Kabanova et al. 2010) indicating that simply presenting dense arrays of oligomannosides that in essence are identical to natural oligomannoses is insufficient to yield the desired responses. The posit here is that the bacterial origin of the Rv3 glycan will serve as a better stimulant for the elicitation of antibodies capable of cross-recognizing oligomannose clusters on the surface of HIV.
While the domain-swapped dimer structure of 2G12 is highly effective at contacting closely spaced glycans such as those on the gp140 trimer, 2G12 is so far the only antibody known with such a structural configuration. However, the recent discovery of 'normal', non-domain-swapped neutralizing antibodies to HIV that recognize mixed glycan/protein epitopes, means that an effective immunogen (Sheriff et al. 1987 ).
Structure of HIV Fab 2G12 with a bacterial oligosaccharide to produce a high-affinity response towards glycans does not necessarily need to elicit domain swapping such as in 2G12. Thus, the structures of these antibodies have revealed other ways of achieving high-affinity carbohydrate recognition, but with the caveat that, in addition to carbohydrate, they also bind peptide segments of the HIV glycoprotein surface. In this regard, it is worth noting that the Rv3 structure reported here also allows identification of locations at which to incorporate modifications to allow for recognition by the more recently identified oligomannose-specific antibodies to HIV, such as those from the PGT128 family of antibodies which do not bind Rv3 heat-killed bacteria (unpublished data). Most broadly neutralizing anti-HIV-1 antibodies are highly somatically mutated; 2G12 for example has an estimated 38/16 amino acid mutations in the heavy/light chains (Huber et al. 2010) . Synthetically constructed, V-gene reverted germline-like precursors of these antibodies do not bind their HIV-1 antigens (Xiao et al. 2009; Hoot et al. 2013 ), begging the question of which B cells were initially activated for evolution of antibodies such as 2G12. Indeed, a previous study showed that, while able to activate engineered mouse B-cell lines displaying domain-exchanged or non-domain-exchanged 2G12 on their surface, neither heat-killed Rv3 bacteria or other current immunogens (i.e., heat-killed engineered yeast, recombinant monomeric and trimeric forms of the HIV-1 envelope glycoprotein or oligodendrons) were able to activate B-cell lines displaying V-gene reverted germline 2G12 ). However, one study has posited that domain exchange may be achievable by as few as 5-7 mutations from the germline (Huber et al. 2010) , suggesting that it may be possible to induce such an exchange using carefully designed immunogens. Furthermore, bacterial carbohydrate epitopes encompassing Kdo sugars have been shown to bind to select sets of germline gene segments in mice (Nguyen et al. 2003; Brooks et al. 2010 Brooks et al. , 2013 ; naive B-cell receptors with affinity for a carbohydrate immunogen based on the Rv3 glycan may similarly exist in the human antibody repertoire. Alternatively, glycoconjugates incorporating tailored oligovalent clusters of the Rv3 OS (or derivatives thereof) may find use as part of an immunization strategy, perhaps in concert with other HIV-1 glycoprotein antigens such as the gp140 SOSIP trimer (Binley et al. 2000; Sanders et al. 2004; Lyumkis et al. 2013) , to drive the elicitation of broadly neutralizing carbohydratespecific antibodies to HIV.
Materials and methods
Rv3 OS isolation
Rhizobium radiobacter Rv3 LOS was isolated from cells as described previously (Clark et al. 2012 ) and the OS moiety cleaved from the lipid A region by mild acid hydrolysis. Briefly, LOS (50 mg) was treated with 1% acetic acid (5 mL, 100°C, 2 h) and the cleaved lipid A removed by centrifugation (5000 rpm, 15 min). The supernatant was chromatographed on a Bio-Gel P2 (Bio-Rad, 1.5 × 100 cm, eluent water, flow = 12 mL/h) and the eluate monitored with a refractive index detector (Knauer K-2301). Fractions giving a positive read-out at the detector were individually freeze-dried and inspected by proton NMR. Pure hexasaccharide (8 mg), containing the D1-like arm, attached to one Kdo residue was isolated (Figure 1 , highlighted structure) and its structure confirmed by 2D NMR.
NMR spectroscopy
NMR experiments were carried out on a Bruker DRX-600 spectrometer equipped with a cryo-probe operating at 298 K. Chemical shift of spectra was recorded in D 2 O and expressed in δ relative to internal acetone (2.225 and 31.45 ppm). Two-dimensional spectra (DQ-COSY, TOCSY, TROESY, gHSQC, gHMBC and gHSQCTOCSY) were measured using standard Bruker software, as reported previously (Clark et al. 2012) . Data processing and analysis were performed with the Bruker Topspin 3 program.
Expression and purification of 2G12
2G12 IgG was produced as previously described by transient co-transfection of 293F cells with two separate plasmids containing the respective light and heavy chain (for sequences, see Kunert et al. 1998) , each preceded by an Ig kappa leader sequence. One week after transfection, the media containing 2G12 IgG was collected and passed over a protein A column (5 mL HiTrap rProtein A FF; GE Healthcare; flow rate 1 mL/min) equilibrated in 1× phosphate-buffered saline (PBS), and the bound IgG was eluted with 0.1 M glycine, pH 2.7, collecting 1.3 mL fractions into tubes containing 0.2 mL 1 M Tris, pH 9. The IgG was further purified by size exclusion chromatography on a Superdex 200 16/60 column with running buffer 20 mM Tris, 150 mM NaCl, pH 8.0. To digest the purified IgG, activated papain was prepared by combining 20.8 µL papain solution (Sigma P3125, 15-30 mg/mL, 16-40 U/mg), 100 µL 100 mM cysteine, 100 µL 10× papain digest buffer (10× = 1 M NaAc, pH 5.5, 3 mM EDTA) and 778 µL MilliQ water and incubating at 37°C for 15 min. Test digests with 0.5, 1, 2 and 4% activated papain were carried out for 1, 2, 3 and 4 h at 37°C, and analyzed by non-reducing SDS-polyacrylamide gel electrophoresis. Based on these results, 2% papain for between 3 and 4 h was chosen for the large-scale cleavage. Fresh-activated papain was prepared as above, and 600 µL was added to 5.5 mL of 2G12 (2.5 mg/mL). The mixture was incubated at 37°C for 3.5 h. The papain was inactivated by the addition of iodoacetamide (37 mg/mL) to a final concentration of 200 mM with incubation at 37°C for 1 h. Fab was then separated from Fc and uncleaved IgG by protein A chromatography, as described at the beginning of this paragraph for the IgG purification. The flow through was collected as Fab and further purified by size exclusion chromatography (Superdex 200 16/60 in 20 mM Tris, 150 mM NaCl, pH 8.0) to ensure that dimeric Fab was obtained . Bound Fc and uncleaved IgG fragments were eluted from the protein A column with 0.1 M glycine, pH 2.7, and discarded. Approximately 5 mg of Fab was obtained from 13.75 mg of IgG. The final product includes the complete 2G12 light chain, and heavy chain residues 1-224 (Kabat numbering), organized as a domain-swapped dimer of Fabs (two light and two heavy chains in one biological functional unit).
Crystallization
2G12 Fab (17 mg/mL, in 20 mM Tris-HCl, 150 mM NaCl, pH 8.0) was mixed with Rv3 OS (100 mg/mL in H 2 O) at a 1 : 3 molar ratio and screened for crystallization at 22°C using the Stura Footprint Screen #1 (Stura et al. 1992) , using sitting drop Cryschem plates (Hampton Research) with 0.4 μL protein mixed with 0.4 μL well solution and a 1 mL well volume. Crystals were obtained in several similar conditions with the highest-resolution data collected from a crystal grown in 33% PEG 600, 0.2 M imidazole malate, pH 5.5 (Condition 1C). The crystal was briefly immersed in a mixture of 30% glycerol and well solution before vitrification by plunging into liquid nitrogen.
Data collection and structure determination
Data were collected at APS beamline 23-ID-D with a MarMosaic300 CCD detector to a high-resolution limit of 1.85 Å resolution. Data collection statistics are compiled in Supplementary data, (Evans 2006) . Some data were lost due to overlapping reflections, so that the final data are 88% complete overall, with a completeness of 77.8% in the highest-resolution shell (1.90-1.85 Å). The effective resolution of the dataset was estimated to be 2.0 Å resolution (Weiss 2001; Urzhumtseva et al. 2013 ). Structures were determined by the molecular replacement method using Phaser (McCoy et al. 2007 ) with 2G12 coordinates from PDB file 1OP5 as a starting model. Refinement was carried out with Phenix (Afonine et al. 2012 ) against all F obs (F > 0.0σF) excluding a randomly chosen R free test set of 1999 reflections (2.6% and refining isotropic B values). Model building was carried out with Coot (Emsley and Cowtan 2004) , carbohydrate geometry was evaluated with pdb-care (Lutteke and von der Lieth 2004; Lutteke et al. 2006 ) and superpositions carried out using the McLachlan algorithm (McLachlan 1982) as implemented in the program ProFit (Martin, ACR, http://www.bioinf.org.uk/software/profit/). Waters were added using the 'Find Water' function in Coot and monitored visually using the 'Check/Delete waters' function, also in Coot.
Figures were generated with Molscript and Bobscript (Kraulis 1991; Esnouf 1999 ). The Fab is numbered with Kabat nomenclature (Kabat et al. 1991 ) and the Rv3 sugar units are numbered as in Figure 1 .
Protein structure accession number
The coordinates and data for the 2G12-Rv3 structure have been deposited with the Protein Data Bank as entry 4RBP.
